click on circles to display study description...

JAVELIN Ovarian 100, 0 NCT02718417

avelumab plus SoC (n=-9) vs. Standard of Care (SoC) (n=-9)

randomized controlled trial

Studied treatment

avelumab in maintenance plus carboplatin/paclitaxel

Control treatment

carboplatin/paclitaxel followed by observation

three-arm study : avelumab alone, avelumab in combination with carboplatin/paclitaxel and carboplatin/paclitaxel followed by observation in maintenance setting following frontline chemotherapy

Patients

metastatic/advanced OC (mOC) - maintenance (M)

Method

open label

P3/ stopped

Remark

data from a planned interim analysis of the Phase III JAVELIN Ovarian 100 study of avelumab* did not support the study’s initial hypothesis, and therefore the alliance made the decision to terminate the trial in alignment with the independent Data Monitoring Committee.